Daniel Estes, Ph.D.


Dan is a Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 8 years.

Dan joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He serves on the boards of Semnur Pharmaceuticals, Outpost Medicine, Sierra Oncology (NASDAQ: SRRA), and Cirius Therapeutics. He has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), PreCision Dermatology (acquired by Valeant), Calibrium (acquired by Novo), and Entasis Therapeutics.

Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy.

Dan received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases. He has authored nine papers in peer-reviewed journals and received several fellowships from the National Institutes of Health. Dan also holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.

Menlo Park

Stanford University (B.S.)
University of Michigan (Ph.D.)

Year Joined
Social Media